Psychometric properties of the 8-item Morisky Medication Adherence Scale in patients taking warfarin

Summary

There is no patient-reported medication adherence measure that has been validated in Singapore. This study aimed to validate the 8-item Morisky Medication Adherence Scale (MMAS) in patients taking warfarin in Singapore. A cross-sectional survey was conducted in a convenience sample of 151 patients taking warfarin at an anticoagulation clinic in 2011. Respondents completed the MMAS in English or Chinese depending on their preference. The MMAS had a Cronbach′s alpha of 0.56 and good criterion-related validity as the scale scores were associated with warfarin refill rates (p = 0.04). Respondents with higher MMAS scores were found to have a higher percentage of International Normalised Ratios (INRs) within the therapeutic range (p = 0.01), higher adherence to diet recommendations (p = 0.02), and less perceived difficulty in taking all medications (p < 0.001); they were also more likely to take warfarin at the same time every day (p < 0.001). Confirmatory factor analysis showed that the eight items loaded onto one factor (RMSEA = 0.03). The sensitivity, specificity, positive predictive value and negative predictive value of the MMAS for identifying patients with poor INR control were 73.0%, 35.6%, 49.5% and 60.5%, respectively, using the time in the therapeutic INR range as the gold standard. This study shows that the 8-item MMAS has good validity and moderate reliability in patients taking warfarin. Future research is needed to investigate the scale′s psychometric properties in other patient populations and clinical settings.

Keywords

Morisky Medication Adherence Scale - medication adherence - anticoagulation - warfarin

• References

• 1 Geerts WH. et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl. 03) 338S-400S.
• 2 Albers GW. et al. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl. 03) 483S-512S.
• 3 Ansell J. et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl. 03) 204S-233S.
• 4 Baglin T P. et al. Guidelines on oral anticoagulation (warfarin): third edition--2005 update. Br J Haematol 2006; 132: 277-285.
• 5 Wittkowsky AK, Devine EB. Frequency and causes of overanticoagulation and underanticoagulation in patients treated with warfarin. Pharmacotherapy 2004; 24: 1311-1316.
• 6 Waterman AD. et al. Effect of warfarin nonadherence on control of the International Normalized Ratio. Am J Health Syst Pharm 2004; 61: 1258-1264.
• 7 Levine MN. et al. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl. 03) 287S-310S.
• 8 Merli GJ, Tzanis G. Warfarin: what are the clinical implications of an out-of-range-therapeutic international normalized ratio?. J Thromb Thrombolysis 2009; 27: 293-299.
• 9 Hylek EM. et al. of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019-1026.
• 10 Hixson-Wallace JA. et al. Effect of regimen complexity on patient satisfaction and compliance with warfarin therapy. Clin Appl Thromb Hemost 2001; 07: 33-37.
• 11 Kimmel SE. et al. The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Arch Intern Med 2007; 167: 229-235.
• 12 Rose AJ. et al. Epidemiology of subtherapeutic anticoagulation in the United States. Circ Cardiovasc Qual Outcomes 2009; 02: 591-597.
• 13 Glader EL. et al. Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke 2010; 41: 397-401.
• 14 Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-497.
• 15 Vermeire E. et al. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 2001; 26: 331-342.
• 16 Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 1999; 21: 1074-1090.
• 17 Morisky DE. et al. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens 2008; 10: 348-354.
• 18 Morisky DE. et al. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24: 67-74.
• 19 Korb-Savoldelli V. et al. Validation of a French Version of the 8-Item Morisky Medication Adherence Scale in Hypertensive Adults. J Clin Hypertens. 2012 in press
• 20 Sakthong P. et al. Psychometric properties of the Thai version of the 8-item Morisky Medication Adherence Scale in patients with type 2 diabetes. Ann Pharmacother 2009; 43: 950-957.
• 21 Al-Qazaz H. et al. The eight-item Morisky Medication Adherence Scale MMAS: translation and validation of the Malaysian version. Diabetes Res Clin Pract 2010; 90: 216-221.
• 22 Ttrindade AJ. et al. Are your patients taking their medicine? Validation of a new adherence scale in patients with inflammatory bowel disease and comparison with physician perception of adherence. Inflamm Bowel Dis 2011; 17: 599-604.
• 23 Reynolds K. et al. Psychometric properties of the osteoporosis-specific morisky medication adherence scale in postmenopausal women with osteoporosis newly treated with bisphosphonates. Ann Pharmacother 2012; 46: 659-670.
• 24 Orensky IA, Holdford DA. Predictors of noncompliance with warfarin therapy in an outpatient anticoagulation clinic. Pharmacotherapy 2005; 25: 1801-1808.
• 25 Cortina JM. What Is Coefficient Alpha? An Examination of Theory and Applications. J Appl Psychol 1993; 78: 98-104.
• 26 Hess LM. et al. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006; 40: 1280-1288.
• 27 Brown TA. Confirmatory Factor Analysis for Applied Research. The Guilford Press; New York: 2006
• 28 Streiner DL. Health Measurement Scales: A Practical Guide to Their Development and Use. 3rd ed. Oxford University Press; USA: 2003
• 29 Krousel-Wood M. et al. New medication adherence scale versus pharmacy fill rates in seniors with hypertension. Am J Manag Care 2009; 15: 59-66.
• 30 Natarajan N. et al. Family practice patients' adherence to statin medications. Can Fam Physician 2007; 53: 2144-2145.
• 31 Agh T. et al. Factors associated with medication adherence in patients with chronic obstructive pulmonary disease. Respiration 2011; 82: 328-334.
• 32 Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med 2008; 31: 213-224.
• 33 Chiquette E. et al. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998; 158: 1641-1647.
• 34 Cohen AT. et al. Will a once-weekly anticoagulant for the treatment and secondary prevention of thromboembolism improve adherence?. Thromb Haemost 2009; 101: 422-427.